Stryker (SYK) is back in focus after its Michigan based sales unit secured a US$100 million contract modification from the US Defense Logistics Agency, lifting the stock around 2.7%.
See our latest analysis for Stryker.
The contract news comes after a mixed period for Stryker, with the stock recording a 6.53% 1 month share price return and an 8.45% 3 month share price return, yet a 1 year total shareholder return that declined 12.36%. This points to improving short term momentum from a weaker recent base.
If this kind of contract driven move has your attention, it could be worth seeing which other medical technology and related players are gaining traction through artificial intelligence in healthcare via the 42 healthcare AI stocks
Stryker appears to be a solid medical technology business, with government contracts adding extra support after the latest US$100 million award. The more practical question now is whether that quality is already fully reflected in the share price.
Most Popular Narrative: 12.1% Undervalued
The most followed narrative currently values Stryker at $386.80 per share, compared with the latest close at $339.98. This frames the recent contract win within a wider upside thesis.
Robust innovation pipeline, particularly in robotic-assisted surgery (Mako platform) and next-generation devices, is driving greater market share, higher average selling prices, and service revenues. This is expected to accelerate both revenue and margin expansion over time. The ongoing industry shift to outpatient and minimally invasive procedures, where Stryker is a leading supplier of ASC infrastructure and advanced surgical solutions, positions the company to benefit from increased procedure volumes and deeper customer penetration, bolstering both revenue and operating leverage.
Want to understand why this narrative supports a higher price than today? The story leans on steady revenue gains, rising margins, and a premium earnings multiple. Curious which assumptions really move that fair value line? The full narrative spells out the numbers behind that view.
Result: Fair Value of $386.80 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Stryker narrative also leans on smooth regulatory approvals and contained supply chain and tariff pressures, which could easily shift and challenge that upside case.
Find out about the key risks to this Stryker narrative.
Another View: Stryker Through The P/E Lens
The SWS DCF model sees Stryker as undervalued, yet the simple P/E check tells a different story. SYK trades on a 35x P/E, compared with 28x for the US Medical Equipment industry, 31.8x for peers, and a fair ratio of 34.4x that the market could move towards. That suggests investors are already paying a premium multiple, so the key question is whether future execution justifies that extra stretch.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If the mixed signals around Stryker leave you undecided, use that as a prompt to act now and weigh both sides carefully. To see the full balance of potential upsides and concerns, review the 3 key rewards and 2 important warning signs
Looking for more investment ideas beyond Stryker?
If Stryker has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to quickly surface other opportunities that match your preferred balance of risk and reward.
- Spot potential value opportunities early by scanning companies that look mispriced compared with their quality through the 52 high quality undervalued stocks.
- Strengthen the defensive side of your portfolio by focusing on businesses highlighted in the 78 resilient stocks with low risk scores.
- Track lesser known companies with solid fundamentals through the screener containing 20 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com